Cue Biopharma (NASDAQ:CUE) CEO Shao-Lee Lin Sells 40,000 Shares of Stock

Cue Biopharma, Inc. (NASDAQ:CUE) CEO Shao-Lee Lin sold 40,000 shares of Cue Biopharma stock in a transaction that occurred on Wednesday, August 12th. The shares were sold at an average price of $27.10, for a total transaction of $1,084,000.00. Following the sale, the chief executive officer owned 724,253 shares of the company’s stock, valued at approximately $19,627,256.30. The trade was a 5.23% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Shao-Lee Lin also recently made the following trade(s):

• On Thursday, August 13th, Shao-Lee Lin sold 18,258 shares of Cue Biopharma stock. The stock was sold at an average price of $28.62, for a total value of $522,543.96.

Cue Biopharma Stock Up 10.0%

Shares of CUE stock opened at $34.20 on Friday. The stock has a market cap of $143.64 million, a P/E ratio of -6.12 and a beta of 2.47. Cue Biopharma, Inc. has a fifty-two week low of $4.97 and a fifty-two week high of $45.50. The business has a fifty day simple moving average of $29.50 and a 200-day simple moving average of $147.28.

Cue Biopharma (NASDAQ:CUE) last announced its earnings results on Friday, August 14th. The company reported ($24.14) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.69) by ($22.45). Cue Biopharma had a negative return on equity of 98.30% and a negative net margin of 59.65%.The business had revenue of $7.88 million for the quarter, compared to analyst estimates of $3.00 million.

Institutional Trading of Cue Biopharma

A number of hedge funds have recently made changes to their positions in CUE. Northwestern Mutual Wealth Management Co. boosted its stake in shares of Cue Biopharma by 730.0% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 83,000 shares of the company’s stock valued at $57,000 after purchasing an additional 73,000 shares during the period. Squarepoint Ops LLC purchased a new stake in Cue Biopharma during the 3rd quarter worth $62,000. Stifel Financial Corp lifted its holdings in Cue Biopharma by 25.4% in the 4th quarter. Stifel Financial Corp now owns 246,556 shares of the company’s stock worth $75,000 after buying an additional 50,000 shares in the last quarter. Texas Capital Bank Wealth Management Services Inc boosted its position in Cue Biopharma by 1,231.2% in the 4th quarter. Texas Capital Bank Wealth Management Services Inc now owns 440,670 shares of the company’s stock valued at $135,000 after buying an additional 407,568 shares during the last quarter. Finally, Boothbay Fund Management LLC grew its stake in shares of Cue Biopharma by 15.3% during the fourth quarter. Boothbay Fund Management LLC now owns 704,297 shares of the company’s stock valued at $215,000 after acquiring an additional 93,333 shares in the last quarter. Hedge funds and other institutional investors own 35.04% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on CUE. Wall Street Zen downgraded shares of Cue Biopharma from a “buy” rating to a “hold” rating in a research note on Saturday. Weiss Ratings upgraded shares of Cue Biopharma from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday, May 18th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Cue Biopharma presently has an average rating of “Sell”.

About Cue Biopharma

Cue Biopharma is a clinical‐stage biotechnology company focused on the development of next‐generation immunotherapies for cancer and infectious diseases. The company’s proprietary platform, known as Cytokine Release & Targeting (CRT), is designed to deliver cytokine payloads directly to antigen‐specific T cells in order to enhance immune responses within targeted tissues. This approach aims to improve the therapeutic index of cytokine treatments by limiting systemic exposure and potentiating localized immune activation.

Founded in 2015 and headquartered in Cambridge, Massachusetts, Cue Biopharma has advanced multiple lead programs into early‐stage clinical studies.